329 related articles for article (PubMed ID: 7891985)
1. Effects of apraclonidine on aqueous humor dynamics in human eyes.
Toris CB; Tafoya ME; Camras CB; Yablonski ME
Ophthalmology; 1995 Mar; 102(3):456-61. PubMed ID: 7891985
[TBL] [Abstract][Full Text] [Related]
2. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
3. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
Toris CB; Camras CB; Yablonski ME
Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
[TBL] [Abstract][Full Text] [Related]
4. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Toris CB; Camras CB; Yablonski ME
Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
[TBL] [Abstract][Full Text] [Related]
5. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Maus TL; Nau C; Brubaker RF
Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
Lim KS; Nau CB; O'Byrne MM; Hodge DO; Toris CB; McLaren JW; Johnson DH
Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
[TBL] [Abstract][Full Text] [Related]
8. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study.
Dinslage S; Hueber A; Diestelhorst M; Krieglstein G
Graefes Arch Clin Exp Ophthalmol; 2004 Aug; 242(8):654-60. PubMed ID: 15241610
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanism for the additivity of pilocarpine and latanoprost.
Toris CB; Zhan GL; Zhao J; Camras CB; Yablonski ME
Am J Ophthalmol; 2001 Jun; 131(6):722-8. PubMed ID: 11384567
[TBL] [Abstract][Full Text] [Related]
11. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients.
Toris CB; Zhan G; Camras CB
Arch Ophthalmol; 2004 Dec; 122(12):1782-7. PubMed ID: 15596580
[TBL] [Abstract][Full Text] [Related]
12. Effects of topical epinephrine on aqueous humor dynamics in the cat.
Wang YL; Toris CB; Zhan G; Yablonski ME
Exp Eye Res; 1999 Apr; 68(4):439-45. PubMed ID: 10192801
[TBL] [Abstract][Full Text] [Related]
13. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy.
Gulati V; Fan S; Zhao M; Maslonka MA; Gangahar C; Toris CB
Arch Ophthalmol; 2012 Jun; 130(6):677-84. PubMed ID: 22332206
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
Johnson TV; Fan S; Zhan G; Camras CB; Toris CB
J Glaucoma; 2010 Aug; 19(6):356-64. PubMed ID: 20179619
[TBL] [Abstract][Full Text] [Related]
16. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics.
Brubaker RF; Schoff EO; Nau CB; Carpenter SP; Chen K; Vandenburgh AM
Am J Ophthalmol; 2001 Jan; 131(1):19-24. PubMed ID: 11162974
[TBL] [Abstract][Full Text] [Related]
17. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).
Gharagozloo NZ; Relf SJ; Brubaker RF
Ophthalmology; 1988 Sep; 95(9):1217-20. PubMed ID: 3062536
[TBL] [Abstract][Full Text] [Related]
18. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.
Wang RF; Lee PY; Mittag TW; Podos SM; Serle JB; Becker B
Arch Ophthalmol; 1998 Sep; 116(9):1213-6. PubMed ID: 9747682
[TBL] [Abstract][Full Text] [Related]
19. Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise.
Rosenberg LF; Krupin T; Ruderman J; McDaniel DL; Siegfried C; Karalekas DP; Grewal RK; Gieser DK; Williams R
Ophthalmology; 1995 Sep; 102(9):1312-8. PubMed ID: 9097768
[TBL] [Abstract][Full Text] [Related]
20. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
